Darlix A, Louvel G, Fraisse J, Jacot W, Brain E, Debled M, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer. 2019;121(12):991–1000. https://doi.org/10.1038/s41416-019-0619-y.
Article CAS PubMed PubMed Central Google Scholar
Kuksis M, Gao Y, Tran W, Hoey C, Kiss A, Komorowski AS, et al. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(6):894–904. https://doi.org/10.1093/neuonc/noaa285.
Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter I, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–7. https://doi.org/10.1002/cncr.11436.
Brufsky AM, Mayer M, Rugo HS, Kaufman PA, Tan-Chiu E, Tripathy D, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834–43. https://doi.org/10.1158/1078-0432.CCR-10-2962.
Article CAS PubMed Google Scholar
Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013;22(4):525–31. https://doi.org/10.1016/j.breast.2012.12.006.
Brosnan EM, Anders CK. Understanding patterns of brain metastasis in breast cancer and designing rational therapeutic strategies. Ann Transl Med. 2018;6(9):163. https://doi.org/10.21037/atm.2018.04.35.
Article CAS PubMed PubMed Central Google Scholar
Untch M., Geyer C.E., Huang C., Loibl S., Wolmark N., Mano M.S., et al. Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: an update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Eur Society Med Oncol (ESMO) 2019. p. v851-934.
Gondi V, Bauman G, Bradfield L, Burri SH, Cabrera AR, Cunningham DA, et al. Radiation therapy for brain metastases: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(4):265–82. https://doi.org/10.1016/j.prro.2022.02.003.
Ramakrishna N, Anders CK, Lin NU, Morikawa A, Temin S, Chandarlapaty S, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO Guideline Update. J Clin Oncol. 2022;40(23):2636–55. https://doi.org/10.1200/JCO.22.00520.
Article CAS PubMed Google Scholar
Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. 2013;15(10):1429–37. https://doi.org/10.1093/neuonc/not114.
Article CAS PubMed PubMed Central Google Scholar
Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol. 2020;38(10):1019–29. https://doi.org/10.1200/JCO.19.02767.
Article PubMed PubMed Central Google Scholar
Vogelbaum MA, Brown PD, Messersmith H, Brastianos PK, Burri S, Cahill D, et al. Treatment for brain metastases: ASCO-SNO-ASTRO Guideline. J Clin Oncol. 2022;40(5):492–516. https://doi.org/10.1200/JCO.21.02314.
Article CAS PubMed Google Scholar
Niwinska A. Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment. Clin Exp Metastasis. 2016;33(7):677–85. https://doi.org/10.1007/s10585-016-9802-1.
Article CAS PubMed Google Scholar
Mounsey LA, Deal AM, Keith KC, Benbow JM, Shachar SS, Zagar T, et al. Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies. Clin Breast Cancer. 2018;18(1):29–37. https://doi.org/10.1016/j.clbc.2017.07.017.
Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, et al. Continued endocrine therapy is associated with improved survival in patients with breast cancer brain metastases. Clin Cancer Res. 2019;25(9):2737–44. https://doi.org/10.1158/1078-0432.CCR-18-1968.
Article CAS PubMed Google Scholar
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942–50. https://doi.org/10.1056/NEJMoa2114663.
Article CAS PubMed Google Scholar
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307–16. https://doi.org/10.1056/NEJMoa1903765.
Article CAS PubMed Google Scholar
Goetz MP, Toi M, Huober J, Sohn J, Trendan O, Park IH, et al. MONARCH 3: interim overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor in patients with HR+, HER2- advanced breast cancer. EurSoc Med Oncol (ESMO) 2022. p. LBA15.
Finn RS, Rugo HS, Dieras VC, Harbeck N, Im, SA, Gelmon KA, et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. AmSoc Clin Oncol (ASCO) 2022. p. LBA1003.
Tolaney SM, Sahebjam S, Le Rhun E, Bachelot T, Kabos P, Awada A, et al. A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res. 2020;26(20):5310–9. https://doi.org/10.1158/1078-0432.CCR-20-1764.
Article CAS PubMed Google Scholar
Cottu P, Ring A, Abdel-Razeq H, Marchetti P, Cardoso F, Salvador Bofill J, et al. Ribociclib plus letrozole in subgroups of special clinical interest with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Subgroup analysis of the phase IIIb CompLEEment-1 trial. Breast. 2022;62:75–83. https://doi.org/10.1016/j.breast.2022.01.016.
Article PubMed PubMed Central Google Scholar
Fitzgerald D.M., Muzikansky A., Pinto C., Henderson L., Walmsley C., Allen R., et al. Association between PIK3CA mutation status and development of brain metastases in HR2+/HER2- metastatic breast cancer. Eur Soc Med Oncol (ESMO) 2019. p. V110.
Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–40. https://doi.org/10.1056/NEJMoa1813904.
Article CAS PubMed Google Scholar
Batalini F, Moulder SL, Winer EP, Rugo HS, Lin NU, Wulf GM. Response of brain metastases from PIK3CA-mutant breast cancer to alpelisib. JCO Precis Oncol 2020;4. https://doi.org/10.1200/PO.19.00403.
National Comprehensive Cancer Network (NCCN). Central nervous system cancers, Version 2.2022.
McDonnell DP, Wardell SE, Chang CY, Norris JD. Next-generation endocrine therapies for breast cancer. J Clin Oncol. 2021;39(12):1383–8. https://doi.org/10.1200/JCO.20.03565.
Article CAS PubMed PubMed Central Google Scholar
Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246–56. https://doi.org/10.1200/JCO.22.00338.
Article CAS PubMed PubMed Central Google Scholar
Conlan MG, de Vries EFJ, Glaudemans A, Wang Y, Troy S. Pharmacokinetic and pharmacodynamic studies of elacestrant, a novel oral selective estrogen receptor degrader, in healthy post-menopausal women. Eur J Drug Metab Pharmacokinet. 2020;45(5):675–89. https://doi.org/10.1007/s13318-020-00635-3.
Article CAS PubMed PubMed Central Google Scholar
Hodges-Gallagher L., Parisian A.D., Sun R., Myles D.C., Klein P.M., Harmon C.L., et al. The complete estrogen receptor antagonist (CERAN) OP-1250 shrinks ER+ brain metastases in an intracranial xenograft tumor model expressing mutant ESR1. Am Assoc Cancer Res (AACR) 2021. p. LB122.
Hodges-Gallagher L., Sun R., Myles D., Klein P., Zujewski J.A., Harmon C., et al. OP-1250: A potent orally available complete antagonist of estrogen receptor-mediated signaling that shrinks wild type and mutant breast tumors. Eur J Cancer (EJC) 2020. p. S55.
Viale G, Niikura N, Tokunaga E, Alynikova O, Hayashi N, Sohn J, O'Brien C, et al. Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics. Am Soc Clin Oncol (ASCO) 2022. p. 1087.
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–62. https://doi.org/10.1200/JCO.19.02488.
Article CAS PubMed Google Scholar
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.
Article CAS PubMed Google Scholar
Epaillard N, Lusque A, Pistilli B, Andre F, Bachelot T, Pierga JY, et al. Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial. Eur Soc Med Oncol (ESMO) 2022 p. S656.
Perez-Garcia JM, Batista MV, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH Trial. Neuro Oncol. 2023;25(1):157–66. https://doi.org/10.1093/neuonc/noac144.
Rugo HS, Bardia A, Marme F, Cortes J, Schmid P, Loirat D, et al. Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Am Soc Clin Oncol (ASCO) 2022. p. LBA1001.
Rugo HS, Bardia, A, Marme F, Cortes J, Schmid P, Loirat D, et al. Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). Eur Soc Med Oncol (ESMO) 2022. p. S808-S69.
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–34. https://doi.org/10.1056/NEJMoa1413513.
Article CAS PubMed PubMed Central Google Scholar
Swain SM, Baselga J, Miles D, Im YH, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol. 2014;25(6):1116–21. https://doi.org/10.1093/annonc/mdu133.
Article CAS PubMed PubMed Central Google Scholar
Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36(27):2804–7. https://doi.org/10.1200/JCO.2018.79.2713.
Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54. https://doi.org/10.1056/NEJMoa2115022.
Article CAS PubMed Google Scholar
Hurvitz S, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. San Antonio Breast Cancer Sym (SABCS) 2021. p. GS3-01.
Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–7. https://doi.org/10.1038/s41591-022-01935-8.
留言 (0)